This latest combination formulation of four anti-HIV drugs reflects the continuing need for new single and combination treatments for this disease.

Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet “Quad” HIV Regimen

The Trana HIV 201 High-Throughput (HTS) Assay – designed to identify compounds that inhibit the use of tRNA by HIV – has the ability to select compounds with anti-HIV bioactivity. Because tRNA is essential for HIV replication, disruption of the virus’ ability to use tRNA would represent a novel target for anti-HIV drug therapy.  Learn ...

New high-throughput screening assay exploits transfer RNA (tRNA) as a target for inhibition…

CARY, NC (June 27, 2011) – Trana Discovery, Inc., a drug discovery technology company, today announced the availability of a new High-Throughput Screening (HTS) assay capable of selectively identifying compounds that inhibit the reproduction of Staphylococcus aureus bacteria through a unique mechanism of action: the inhibition of the bacteria’s ability to ...